94. Primary sclerosing cholangitis Clinical trials / Disease details

Clinical trials : 142 / Drugs : 113 - (DrugBank : 37) / Drug target genes : 19 - Drug target pathways : 139

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000012782	2014/02/01	01/02/2014	Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.		Progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.	Group A; phenylbutyrate 6g (Child 100mg/kg)/day 7days Group B; phenylbutyrate 6g (Child 100mg/kg)/day 3days and 12g (Child 200mg/kg)/day 4days Group C; phenylbutyrate 6g (Child 100mg/kg)/day 1day, phenylbutyrate 12g (Child 200mg/kg)/day 2days and phenylbutyrate 21g (Child 300mg/kg)/day 4days	Juntendo University	NULL	Pending	Not applicable	Not applicable	Male and Female	2	Not selected	Japan
2	JPRN-UMIN000003802	2010/04/01	22/06/2010	Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.		Progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.	phenylbutyrate(Child 250mg/kg/day)for 1-4months : phenylbutyrate(Child 350mg/kg/day)for 1-4months : phenylbutyrate(Child 500mg/kg/day)for 1-4months	Saiseikai Yokohama City Tobu Hospital	Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo (Tokyo)	Recruiting	Not applicable	Not applicable	Male and Female	15	Not selected	Japan